Hepatocellular Carcinoma: Essentials Interventional Radiologists Need to Know

Liver cancer is a leading cause of death worldwide and the second most common cause of death for cancer at global level. The most common type of liver cancer is hepatocellular carcinoma (HCC) that accounts for more than 85% of primary liver malignancies [1, 2]. Other types are cholangiocarcinoma and...

Full description

Saved in:
Bibliographic Details
Published in:Cardiovascular and interventional radiology 2019-09, Vol.42 (9), p.1262-1270
Main Authors: D’Avola, Delia, Bilbao, Jose I., Sangro, Bruno
Format: Article
Language:English
Subjects:
Alcohol
Biomarkers
BIOMEDICAL RADIOGRAPHY
Cancer therapies
Cardiology
Cholangiocarcinoma
Chronic infection
Cirrhosis
Clinical trials
Death
DIAGNOSIS
Health risks
Hepatitis
Hepatitis B
Hepatocellular carcinoma
Hepatology
HEPATOMAS
Imaging
Immunization
Infections
Levels
Liver
Liver cancer
Liver cirrhosis
Liver diseases
Medicine
Medicine & Public Health
Mortality
Nuclear Medicine
Radiology
RADIOLOGY AND NUCLEAR MEDICINE
Review
Screening
Serum levels
THERAPY
Tumors
Ultrasound
Viruses
α-Fetoprotein
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Liver cancer is a leading cause of death worldwide and the second most common cause of death for cancer at global level. The most common type of liver cancer is hepatocellular carcinoma (HCC) that accounts for more than 85% of primary liver malignancies [1, 2]. Other types are cholangiocarcinoma and rare tumors such as angiosarcoma or hepatoblastoma. Recognition of chronic liver disease as the main cause of HCC allows running screening programs for death prevention through early detection. Surveillance is universally recommended for patients with cirrhosis or with chronic hepatitis B infection at high risk of HCC development [2, 10, 11]. Several scores can help evaluate the risk of HCC in patients with chronic hepatitis B [12–14]. The recommended screening procedure is liver ultrasound examination every 6 months. No strong evidence supports the practice of measuring serum levels of the biomarker alpha-fetoprotein (AFP) for screening purposes.
ISSN:0174-1551
1432-086X
DOI:10.1007/s00270-019-02221-w